Observatory · observe first
Follow the allocation change
Matched S&P 500 members → sector → industry → sub-industry → company. Each step uses the same percentage points.
Historical time machine
Historical observation
20182026
1 · Sector
Weight and 12M allocation change
2 · Industry
Inside Health Care
Pharmaceuticals4.70%-1.12 ppManaged Health Care2.07%-0.56 ppBiotechnology2.40%-0.49 ppLife Sciences Tools & Services1.64%-0.40 ppHealth Care Services0.70%-0.26 ppHealth Care Equipment2.89%-0.16 ppHealth Care Facilities0.22%-0.03 ppHealth Care Supplies0.15%+0.02 ppHealth Care Distributors0.41%-0.02 ppHealth Care Technology0.00%+0.00 pp
3 · Sub-industry
Inside Biotechnology
Biotechnology · weight
2.40%
Industry change · 12M
-0.49 pp
Biotechnology · contribution
-0.493 pp
Company participation
100%
of industry constituents above their 6M weight average
4 · Companies driving this sub-industry
Dec 2023 · sorted by absolute contribution to 12-month change
| Company | Country | Market cap | Universe weight | 3M contribution | 12M contribution | 12M price return | Above 6M weight average |
|---|---|---|---|---|---|---|---|
| AbbVie → ABBV | United States | $273.6bn | 0.816% | -0.063 pp | -0.215 pp | -0.2% | Yes |
| Moderna → MRNA | United States | $37.9bn | 0.113% | -0.018 pp | -0.136 pp | -44.6% | Yes |
| Gilead Sciences → GILD | United States | $100.9bn | 0.301% | -0.011 pp | -0.088 pp | -2.0% | Yes |
| Amgen → AMGN | United States | $154.1bn | 0.460% | -0.020 pp | -0.046 pp | +13.5% | Yes |
| Vertex Pharmaceuticals → VRTX | United States | $104.8bn | 0.313% | +0.013 pp | +0.045 pp | +40.9% | Yes |
| Biogen → BIIB | United States | $37.5bn | 0.112% | -0.012 pp | -0.032 pp | -6.6% | Yes |
| Incyte → INCY | United States | $14.1bn | 0.042% | -0.001 pp | -0.023 pp | -21.8% | Yes |
| Regeneron Pharmaceuticals → REGN | United States | $82.5bn | 0.246% | -0.012 pp | +0.001 pp | +21.7% | Yes |
Company contributions use weights among matched S&P 500 members and add through each level without rescaling. Companies without matched shares and prices are omitted. These observations do not establish official index weights or actual fund flows.